1. Japan Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Solasia Pharma KK

Solasia Pharma KK

TTSE:4597
26.00
JPY
-1.00
(-3.70%)
7.10BMarket Cap
Nov 12Next Earn
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
- -
0.29
6.21
12.14
4.98
3.41
12.45
3.87
4.3
7.18
3.67
1.45
1.81
- -
Basic EPS, GAAP
- -
-16.4
-17.43
-11.49
-12.24
-25.98
-17.75
-35.16
-19.04
-16.76
-6.61
-8.9
-3.69
- -
Free Cash Flow per Basic Share
- -
-18.94
-36.08
-24.77
-17.12
-27.67
-14.83
-25.22
-20.25
-16.3
-2.14
-4.74
- -
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
10.93
3.02
11.88
40.85
70.74
67.69
59.43
29.78
19.38
15.85
10.78
4.75
6.15
5.32
Tangible Book Value per Share
-3.39
-13.03
-11.76
10.21
35.59
37.86
29.49
10.57
3.81
6.5
4.36
4.75
6.15
5.32
Basic Weighted Avg Shares
84
41
37
41
82
93
105
117
130
152
168
218
238
256
Sales/Revenue/Turnover
- -
12
229
501
410
318
1,310
454
559
1,092
617
316
429
- -
Operating Margin (%)
- -
-5,873.59
-306.11
-92.25
-246.34
-760.69
-134.5
-906.61
-432.92
-226.28
-184.6
-617.09
-200.47
- -
Depreciation Expense
- -
- -
1
1
- -
153
475
496
495
534
500
195
- -
- -
Net Income, GAAP
- -
-677
-644
-474
-1,007
-2,422
-1,867
-4,127
-2,478
-2,548
-1,112
-1,941
-876
- -
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
- -
-5,664.62
-280.6
-94.64
-245.61
-761.64
-142.52
-909.03
-443.29
-233.33
-180.23
-614.24
-204.2
- -
Working Capital
362
358
1,964
896
3,114
3,885
3,377
1,190
405
1,028
683
968
1,466
1,238
LT Debt
497
1,321
2,867
- -
- -
- -
27
21
37
- -
27
12
16
47
Total Equity
919
254
999
3,433
6,208
7,087
6,917
3,652
2,587
2,662
1,875
1,035
1,620
1,452
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
-115.52
-102.82
-21.41
-20.89
-36.43
-26.66
-78.1
-79.44
-97.09
-49.02
-133.4
-65.99
- -

Capital Structure

JPY

•

in mil. unless spec.
Jun'24
Mar'26
Jun'26
ST Debt
33
- -
31
LT Borrowings
- -
- -
- -
LT Finance Leases
11
- -
47
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
200
273
273
Market Capitalization
5,986
8,463
7,098

Working Capital

JPY

•

in mil. unless spec.
Jun'24
Mar'26
Jun'26
Total Current Assets
1,173
- -
1,616
Cash, Cash Equivalents & STI
942
- -
1,289
Accounts Receivable, Net
56
- -
22
Inventories
138
- -
261
Total Current Liabilities
303
- -
378
Payables & Accruals
- -
- -
- -
ST Debt
33
- -
31
Deferred Revenue
- -
- -
- -

Growth Rates

JPY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
24.5%
-8.82%
56.52%
Free Cash Flow
- -
- -
- -
Net Income, GAAP
25.08%
-14.76%
-54.87%
Sales/Revenue/Turnover
38.64%
12.39%
35.76%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

JPY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
11
60
- -
- -
316
2025
- -
- -
- -
- -
429
2026
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

JPY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-1.78
-1.57
- -
- -
-8.9
2025
- -
- -
- -
- -
-3.69
2026
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

JPY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Yoshihiro Arai
Full Time Employees
22
Sector
Health technology
Industry
Pharmaceuticals: major
Address
Sumitomo Fudosan Shiba-Koen Tower Tokyo TY Japan 105-0011
IPO Date
Mar 24, 2017
Website
solasia.co.jp
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Solasia Pharma K.K. operates as a specialty pharmaceutical company, dedicated to the development and commercialization of innovative oncology treatments throughout Japan and other Asian territories. The company offers Episil® oral liquid (SP-03) for the management and relief of oral pain associated with mucositis or stomatitis, common side effects of chemotherapy and radiation therapy for cancer. Additionally, Sancuso® (SP-01) provides a transdermal delivery system for granisetron, an anti-emetic medication used to prevent chemotherapy-induced nausea and vomiting. Within its portfolio, Solasia Pharma also features DARVIAS® (SP-02), an antineoplastic injection recently approved and launched in Japan for treating relapsed or refractory peripheral T-cell lymphoma, with regulatory applications also proceeding in Latin American countries such as Colombia and Peru. The pipeline includes SP-04, undergoing preclinical evaluation for chemotherapy-induced peripheral neuropathy, now with a focus on taxane-induced conditions. Furthermore, SP-05 (Arfolitixorin), designed to augment the anti-tumor effectiveness of fluorouracil in various solid tumors like colorectal cancer, has resumed its development pathway, with Japanese Phase II trials anticipated in 2025-2026. Established in 2006, Solasia Pharma K.K. is headquartered in Tokyo, Japan.